{"id":"beacopp-regimen","safety":{"commonSideEffects":[{"rate":"70-90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"60-80","effect":"Nausea and vomiting"},{"rate":"30-50","effect":"Mucositis"},{"rate":"80-90","effect":"Alopecia"},{"rate":"20-40","effect":"Infection"},{"rate":"5-15","effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":"5-10","effect":"Pulmonary toxicity (bleomycin-related)"},{"rate":"50-90","effect":"Infertility/gonadal dysfunction"},{"rate":"5-10","effect":"Secondary malignancies"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BEACOPP is an intensive polychemotherapy regimen designed for Hodgkin lymphoma treatment. It works through multiple mechanisms: alkylating agents (cyclophosphamide, procarbazine) cross-link DNA; topoisomerase inhibitors (etoposide) prevent DNA unwinding; anthracyclines (doxorubicin) intercalate DNA and generate reactive oxygen species; vinca alkaloids (vincristine) disrupt microtubule formation; and bleomycin causes DNA strand breaks. The combination targets rapidly dividing malignant cells while prednisone provides immunosuppression and anti-inflammatory effects.","oneSentence":"BEACOPP is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:46.318Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma, advanced stages (IIB-IV)"},{"name":"Hodgkin lymphoma, high-risk disease"}]},"trialDetails":[{"nctId":"NCT07234487","phase":"PHASE2","title":"Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2024-10-14","conditions":"Hodgkin Lymphoma","enrollment":178},{"nctId":"NCT03159897","phase":"PHASE3","title":"FIL Study on ABVD DD-DI as Upfront Therapy in HL.","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2017-08-01","conditions":"Hodgkin Lymphoma","enrollment":500},{"nctId":"NCT00049595","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-08","conditions":"Lymphoma","enrollment":552},{"nctId":"NCT00005584","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-10","conditions":"Lymphoma","enrollment":1649},{"nctId":"NCT02661503","phase":"PHASE3","title":"HD21 for Advanced Stages","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cologne","startDate":"2016-07","conditions":"Classical Hodgkin Lymphoma","enrollment":1500},{"nctId":"NCT00678327","phase":"PHASE3","title":"Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University College, London","startDate":"2008-08-29","conditions":"Lymphoma","enrollment":1202},{"nctId":"NCT06263530","phase":"","title":"Prognostic Significance of ctDNA in HL","status":"RECRUITING","sponsor":"Interni hematologicka klinika FNKV","startDate":"2022-01-02","conditions":"Prognostic Cancer Model","enrollment":500},{"nctId":"NCT01390584","phase":"PHASE2","title":"Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-05-24","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT05490953","phase":"PHASE4","title":"Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"University of Guadalajara","startDate":"2022-07-11","conditions":"Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT00822120","phase":"PHASE2","title":"S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-07","conditions":"Lymphoma, Nonneoplastic Condition","enrollment":371},{"nctId":"NCT01118026","phase":"PHASE2","title":"Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-09","conditions":"Lymphoma","enrollment":101},{"nctId":"NCT02298283","phase":"PHASE2","title":"Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2015-04","conditions":"Hodgkin Lymphoma","enrollment":40},{"nctId":"NCT00433433","phase":"PHASE3","title":"Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2006-10","conditions":"Lymphoma","enrollment":1952},{"nctId":"NCT00515554","phase":"PHASE3","title":"HD18 for Advanced Stages in Hodgkins Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2008-05","conditions":"Hodgkins Lymphoma","enrollment":1500},{"nctId":"NCT01569204","phase":"PHASE2","title":"Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2012-10","conditions":"Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT02800447","phase":"NA","title":"Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2016-06","conditions":"Advanced Hodgkin's Lymphoma","enrollment":92},{"nctId":"NCT00795613","phase":"PHASE2","title":"Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)","status":"UNKNOWN","sponsor":"Ospedale Santa Croce-Carle Cuneo","startDate":"2008-06","conditions":"HODGKIN LYMPHOMA","enrollment":450},{"nctId":"NCT00877747","phase":"","title":"Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Ospedale Santa Croce-Carle Cuneo","startDate":"2006-01","conditions":"Hodgkin Lymphoma","enrollment":160},{"nctId":"NCT01251107","phase":"PHASE3","title":"Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2000-03","conditions":"Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT01304849","phase":"NA","title":"Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes","status":"COMPLETED","sponsor":"Cancer Institute WIA","startDate":"2011-01","conditions":"Hodgkin's Lymphoma","enrollment":50},{"nctId":"NCT00392314","phase":"PHASE2","title":"Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision.","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2006-10","conditions":"Hodgkin Lymphoma","enrollment":365},{"nctId":"NCT00004010","phase":"PHASE2","title":"Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1999-10","conditions":"Lymphoma","enrollment":99},{"nctId":"NCT01468740","phase":"PHASE2","title":"Prospective Study on HIV-related Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Harlachinger Krebshilfe e.V.","startDate":"2004-03","conditions":"HIV-associated Hodgkin Lymphoma","enrollment":130},{"nctId":"NCT00264953","phase":"PHASE3","title":"HD11 for Intermediate Stages","status":"COMPLETED","sponsor":"University of Cologne","startDate":"1998-05","conditions":"Hodgkin´s Lymphoma","enrollment":1395},{"nctId":"NCT00443677","phase":"PHASE3","title":"Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)","status":"COMPLETED","sponsor":"Gruppo Italiano Studio Linfomi","startDate":"2000-04","conditions":"Advanced Hodgkin Disease","enrollment":307},{"nctId":"NCT00305149","phase":"NA","title":"Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"1999-07","conditions":"Classical Hodgkin Lymphoma, Nodular Sclerosis, Mixed Cellularity","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BEACOPP regimen","genericName":"BEACOPP regimen","companyName":"SWOG Cancer Research Network","companyId":"swog-cancer-research-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BEACOPP is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms. Used for Hodgkin lymphoma, advanced stages (IIB-IV), Hodgkin lymphoma, high-risk disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}